Lyra Therapeutics (LYRA) Institutional Ownership $6.36 -0.14 (-2.15%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$6.30 -0.06 (-0.86%) As of 09/25/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Lyra Therapeutics (NASDAQ:LYRA)CurrentInstitutional OwnershipPercentage95.62%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$14.31MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$133.29M Get LYRA Insider Trade Alerts Want to know when executives and insiders are buying or selling Lyra Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data LYRA Institutional Buying and Selling by Quarter Lyra Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Perceptive Advisors LLC255,150$2.29M0.2%-98.0%15.558% 8/15/2025 Bank of America Corp DE28,542$256K0.0%+33.7%1.740% 8/8/2025 Geode Capital Management LLC10,986$98K0.0%-98.9%0.687% 6/27/2025 Goldman Sachs Group Inc.370,194$47K0.0%-33.4%27.834% 5/16/2025Goldman Sachs Group Inc.370,194$47K0.0%-33.4%0.559% 2/17/2025Two Sigma Investments LP209,997$43K0.0%-25.7%0.321% 2/17/2025Two Sigma Advisers LP385,500$80K0.0%-16.3%0.589% 2/17/2025BNP Paribas Financial Markets244,920$51K0.0%N/A0.374% 2/14/2025Samsara BioCapital LLC1,965,689$406K0.1%-29.3%3.003% 2/14/2025Northern Trust Corp286,310$59K0.0%+56.2%0.437% Get the Latest News and Ratings for LYRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025ADAR1 Capital Management LLC533,200$110K0.0%N/A0.815% 2/12/2025Geode Capital Management LLC885,966$183K0.0%+15.3%1.353% 2/12/2025JPMorgan Chase & Co.156,442$32K0.0%+161.8%0.239% 11/15/2024State Street Corp488,720$126K0.0%+88.1%0.747% 8/6/2024Acadian Asset Management LLC985,631$271K0.0%N/A1.617% 7/12/2024Rosalind Advisors Inc.1,034,773$286K0.2%-9.6%1.697% 5/17/2024Ikarian Capital LLC1,056,829$6.57M0.7%-15.7%1.733% 5/10/2024Vanguard Group Inc.1,481,481$9.22M0.0%+38.3%2.430% 4/25/2024Rosalind Advisors Inc.1,144,524$7.12M6.7%-39.4%1.916% 2/15/2024Parkman Healthcare Partners LLC754,885$3.96M0.6%+20.8%1.436% 2/14/2024Vestal Point Capital LP3,000,000$15.72M1.7%N/A5.708% 2/13/2024Armistice Capital LLC1,088,000$5.70M0.1%-29.8%2.070% 2/7/2024Jump Financial LLC16,737$88K0.0%N/A0.032% 1/25/2024Heritage Wealth Management Inc. Texas10,000$52K0.0%N/A0.019% 12/6/2023Citigroup Inc.67,677$265K0.0%N/A0.129% 11/15/2023Armistice Capital LLC1,550,000$6.06M0.1%-61.4%2.949% 11/14/2023Prescott Group Capital Management L.L.C.30,000$117K0.0%N/A0.057% 10/24/2023Bank of New York Mellon Corp18,621$73K0.0%N/A0.038% 8/24/2023Perceptive Advisors LLC12,757,562$52.43M1.5%+39.5%25.747% 8/14/2023Samsara BioCapital LLC2,780,261$11.43M2.0%+56.4%8.733% 8/14/2023Pura Vida Investments LLC1,413,242$5.72M0.8%-29.2%4.439% 8/10/2023Letko Brosseau & Associates Inc.31,900$131K0.0%N/A0.100% 2/15/2023Nantahala Capital Management LLC2,220,830$6.97M0.5%-1.1%6.977% 2/14/2023Pura Vida Investments LLC2,157,298$6.77M0.3%-14.1%6.778% 11/15/2022Pura Vida Investments LLC2,510,302$12.58M0.7%-2.6%7.888% 11/14/2022Boothbay Fund Management LLC34,721$174K0.0%-9.5%0.109% 11/10/2022Nantahala Capital Management LLC2,245,830$11.25M0.7%-5.2%17.262% 8/16/2022Pura Vida Investments LLC2,576,196$14.56M0.8%+394.9%19.802% 8/16/2022CVI Holdings LLC60,822$344K0.0%N/A0.468% 8/15/2022Nantahala Capital Management LLC2,369,668$13.39M0.7%N/A18.214% 8/12/2022Ensign Peak Advisors Inc56,229$318K0.0%+43.6%0.432% 8/12/2022Ikarian Capital LLC347,338$1.96M0.4%-17.8%2.670% 5/16/2022Clearline Capital LP119,924$482K0.1%+84.9%0.922% 2/14/2022Clearline Capital LP64,862$283K0.0%N/A0.499% 2/14/2022Soleus Capital Management L.P.10,000$44K0.0%-95.4%0.077% 2/11/2022Pentwater Capital Management LP71,313$311K0.0%+122.8%0.548% 11/16/2021Two Sigma Advisers LP58,000$529K0.0%+31.8%0.446% 11/15/2021Pura Vida Investments LLC533,417$4.87M0.1%-1.7%4.103% 11/15/2021Marshall Wace LLP12,457$114K0.0%-35.5%0.096% 11/9/2021BlackRock Inc.17,818$163K0.0%-11.4%0.137% 11/4/2021Close Asset Management Ltd7,000$64K0.0%N/A0.054% 8/25/2021Marshall Wace LLP19,321$155K0.0%-58.8%0.149% 8/18/2021Ikarian Capital LLC624,684$5.02M0.4%-20.0%4.805% 8/17/2021Walleye Capital LLC19,093$153K0.0%N/A0.147% 8/17/2021Millennium Management LLC155,135$1.25M0.0%N/A1.193% 8/17/2021Bridgeway Capital Management LLC41,900$336K0.0%-14.5%0.322% 8/16/2021Tibra Equities Europe Ltd40,000$321K0.1%N/A0.308% 8/16/2021Marshall Wace LLP19,321$155K0.0%-58.8%0.149% 8/13/2021Geode Capital Management LLC36,102$289K0.0%-60.0%0.278% 8/13/2021Vanguard Group Inc.220,029$1.77M0.0%+3.8%1.692% 8/12/2021Trexquant Investment LP11,610$93K0.0%N/A0.089% 8/12/2021Ergoteles LLC31,000$249K0.0%N/A0.238% 8/11/2021Deutsche Bank AG76,441$614K0.0%-5.4%0.588% 8/11/2021Susquehanna International Group LLP21,529$173K0.0%N/A0.166% 8/2/2021Advisor Group Holdings Inc.4,434$36K0.0%-89.6%0.034% (Data available from 1/1/2016 forward) LYRA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LYRA shares? During the previous two years, 24 institutional investors and hedge funds held shares of Lyra Therapeutics. The most heavily invested institutionals were Vestal Point Capital LP ($15.72M), Vanguard Group Inc. ($9.22M), Ikarian Capital LLC ($6.57M), Armistice Capital LLC ($5.70M), Parkman Healthcare Partners LLC ($3.96M), Perceptive Advisors LLC ($2.29M), and Samsara BioCapital LLC ($406K).Learn more on Lyra Therapeutics' institutional investors. What percentage of Lyra Therapeutics' stock is owned by institutional investors? 95.62% of Lyra Therapeutics' stock is owned by institutional investors. Learn more on LYRA's institutional investor holdings. Which institutional investors have been buying Lyra Therapeutics' stock? Of the 16 institutional investors that purchased Lyra Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vestal Point Capital LP ($3M), Acadian Asset Management LLC ($985.63K), ADAR1 Capital Management LLC ($533.20K), Vanguard Group Inc. ($410.02K), BNP Paribas Financial Markets ($244.92K), State Street Corp ($228.90K), and Parkman Healthcare Partners LLC ($129.83K). How much institutional buying is happening at Lyra Therapeutics? Institutional investors have bought a total of 1,331,495 shares in the last 24 months. This purchase volume represents approximately $14.31M in transactions. Which of Lyra Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Lyra Therapeutics stock in the last 24 months: Perceptive Advisors LLC ($12.50M), Geode Capital Management LLC ($1.01M), Samsara BioCapital LLC ($814.57K), Goldman Sachs Group Inc. ($370.63K), Two Sigma Advisers LP ($74.80K), and Two Sigma Investments LP ($72.55K). How much institutional selling is happening at Lyra Therapeutics? Institutional investors have sold a total of 14,839,980 shares in the last 24 months. This volume of shares sold represents approximately $133.29M in transactions. Related Companies PSTV Institutional Ownership MLSS Institutional Ownership ECOR Institutional Ownership RBOT Institutional Ownership POCI Institutional Ownership CLGN Institutional Ownership STRR Institutional Ownership COCH Institutional Ownership NRXS Institutional Ownership HSDT Institutional Ownership This page (NASDAQ:LYRA) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.